Search in:

Emerging Microbes & Infections Volume 11, 2022 - Issue 1

Submit an article Journal homepage

Open access

7,513

Views

CrossRef citations to date

Altmetric

Coronaviruses

Omicron: a drug developer’s perspective

Fang “Flora” Fanga Abimmune Biopharma, Inc., San Diego, CA, USACorrespondence[email protected]

Pei-Yong Shib Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, TX, USA

Pages 208-211 | Received 22 Dec 2021, Accepted 22 Dec 2021, Published online: 04 Jan 2022

Cite this article
https://doi.org/10.1080/22221751.2021.2023330
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (23)

Igor José dos Santos Nascimento & Ricardo Olimpio de Moura. (2023) Would the Development of a Multitarget Inhibitor of 3CLpro and TMPRSS2 be Promising in the Fight Against SARS-CoV-2?. Medicinal Chemistry 19:5, pages 405-412.
Crossref

Xijing Qian, Bingan Wu, Xiang Chen, Haoran Peng, Miao Liu, Hailin Tang, Zhengmei Xu, Chen Xu & Zhongtian Qi. (2023) Multi‐omic and comparative analyses revealed monocyte‐derived alpha‐defensin‐1 correlated with COVID‐19 severity and inhibited SARS‐CoV‐2 infection. Journal of Medical Virology 95:6.
Crossref

Jia Wang, Yan Chen, Jing Huang, Chenguang Niu, Pengfei Zhang, Keyong Yuan, Xiaohan Zhu, Qiaoqiao Jin, Shujun Ran & Zhengwei Huang. (2023) Prevalence of taste and smell dysfunction in mild and asymptomatic COVID-19 patients during Omicron prevalent period in Shanghai, China: a cross-sectional survey study. BMJ Open 13:3, pages e067065.
Crossref

Michael Y.T. Chow, Harry W. Pan, Han Cong Seow & Jenny K.W. Lam. (2023) Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections. Trends in Pharmacological Sciences 44:2, pages 85-97.
Crossref

Siguna MuellerSiguna Mueller. 2023. Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2. Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2 367 413 .

Junichi Yoshida, Kenichiro Shiraishi & Masao Tanaka. (2022) Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events. BMC Infectious Diseases 22:1.
Crossref

Mya Myat Ngwe Tun, Takaya Sakura, Yasuteru Sakurai, Yohei Kurosaki, Daniel Ken Inaoka, Norifumi Shioda, Chris Smith, Jiro Yasuda, Kouichi Morita & Kiyoshi Kita. (2022) 5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro. Tropical Medicine and Health 50:1.
Crossref

Mohammadreza Saberiyan, Elham Karimi, Zahra Khademi, Parvaneh Movahhed, Amir Safi & Ameneh Mehri-Ghahfarrokhi. (2022) SARS-CoV-2: phenotype, genotype, and characterization of different variants. Cellular & Molecular Biology Letters 27:1.
Crossref

Lei Xie, Junlin Li, Ying Ai, Haolan He, Xiuyun Chen, Mingyu Yin, Wanxi Li, Wenguan Huang, Min-Yi Luo & Jinyang He. (2022) Current strategies for SARS-CoV-2 molecular detection. Analytical Methods 14:45, pages 4625-4642.
Crossref

Fang Flora Fang. (2022) As the virus evolves, so too must we: a drug developer’s perspective. Virology Journal 19:1.
Crossref

Qiuli Chen, Jiawei Zhang, Peter Wang & Zuyong Zhang. (2022) The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. iScience 25:10, pages 105044.
Crossref

Manish Dhawan, AbdulRahman A. Saied, Saikat Mitra, Fahad A. Alhumaydhi, Talha Bin Emran & Polrat Wilairatana. (2022) Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. Biomedicine & Pharmacotherapy 154, pages 113522.
Crossref

Wai Ning Tiffany Tsui, Vaughn Hamill, Lance Noll, Nanyan Lu, Elizabeth Poulsen Porter, Donald Harbidge, Emily Cox, Claire Richardson, Mark Gray, Tesfaalem Sebhatu, Kyle Goerl, Susan Brown, Gregg Hanzlicek, Jamie Retallick & Jianfa Bai. (2022) Molecular detection of SARS‐CoV‐2 and differentiation of Omicron and Delta variant strains. Transboundary and Emerging Diseases 69:5.
Crossref

Xiaoling Cao, Junjie Zai, Qingzhen Zhao, Lilan Xie & Yaoming Li. (2022) Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody. Vaccine 40:40, pages 5757-5763.
Crossref

P. V. Chukhliaev, D. А. Khavkina, J. J. Janibekov & T. A. Ruzhentsova. (2022) Issues of etiotropic therapy in conditions of ‘omicron’ strain of SARS-CoV‑2 spreading: Real practice. Medical alphabet:14, pages 27-30.
Crossref

Stefan Bittmann. (2022) Role of Omicron variant of SARS-CoV-2 in children in Germany. World Journal of Pediatrics 18:4, pages 283-284.
Crossref

Reinhard Schlickeiser & Martin Kröger. (2022) Forecast of Omicron Wave Time Evolution. COVID 2:3, pages 216-229.
Crossref

Muruganantham Bharathi, Bhagavathi Sundaram Sivamaruthi, Periyanaina Kesika, Subramanian Thangaleela & Chaiyavat Chaiyasut. (2022) In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer. Marine Drugs 20:2, pages 148.
Crossref

Ayse Ekinci, Ozgur Tosun & Aylin Islam. (2022) The Knowledge and Attitude of Parents About the Dental Treatment of Their Children During the New Type of Coronavirus Outbreak in Northern Cyprus. Frontiers in Public Health 10.
Crossref

Giorgio Tiecco, Samuele Storti, Melania Degli Antoni, Emanuele Focà, Francesco Castelli & Eugenia Quiros-Roldan. (2022) Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. International Journal of Molecular Sciences 23:4, pages 1987.
Crossref

Emine Erdag. (2022) The Concomitant Use o f Melatonin and Bebtelovimab as a Treatment Strategy for Omicron and Future Variants of Concern. International Journal of Pharmaceutical Research And Allied Sciences 11:4, pages 33-40.
Crossref

康泓王. (2022) Research Progress of SARS-CoV-2 Omicron Variant. Advances in Microbiology 11:02, pages 49-60.
Crossref

Md. Rabiul Islam, Waheeda Nasreen, Ramisa Anjum, Mohammad Shahriar, Arpita Roy, Kuldeep Dhama & Mohiuddin Ahmed Bhuiyan. (2022) Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health. Clinical Pathology 15, pages 2632010X2211249.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Omicron: a drug developer’s perspective

Articles from other publishers (23)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Omicron: a drug developer’s perspective

Citations (23)

Articles from other publishers (23)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date